A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50)
Latest Information Update: 09 Oct 2023
At a glance
- Drugs Vorapaxar (Primary)
- Indications Cardiovascular disorders; Myocardial infarction; Peripheral arterial disorders; Stroke
- Focus Registrational; Therapeutic Use
- Acronyms TRA-2P; TRA2degP-TIMI50; TRA2P-TIMI 50
- Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough Research Institute
- 28 Aug 2023 Results of pooled analysis (n=28892) from TRA2P-TIMI 50 and FOURIER assessing the association between Lp(a) and specific limb outcomes in patients with stable atherosclerotic vascular disease presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
- 07 Nov 2022 Results assessing short- and long-term effects of vorapaxar (V) as compared to Placebo (PL) on the following biomarkers: Angiopoietin-2 (ANGPT2), Angiopoietin-like 4 (ANGPTL4), VEGF, ICAM-1, VCAM-1, E-Selectin (ESEL), von Willebrand Factor (VWF), Thrombomodulin (TM), PAI-1 and PAI-2 from TRA2P-TIMI 50 and TRACER presented at the American Heart Association Scientific Sessions 2022
- 19 Jul 2022 Results published in the Clinical Cardiology